Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||Decitabine + Onvansertib||Phase I||Actionable||In a Phase I trial, Onvansertib (PCM-075) and Dacogen (decitabine) combination therapy resulted in complete response in 33.3% (2/6) and complete response with incomplete hematologic remission in 16.7% (1/6) of evaluable patients with relapsed or refractory acute myeloid leukemia (Ann Oncol, 30 (Supplement 5): v435-v448, 2019; NCT03303339).||detail...|
|PubMed Id||Reference Title||Details|
|Polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with low-dose cytarabine or decitabine in patients with relapsed/refractory acute myeloid leukaemia in phase Ib||Full reference...|